Page 34 - CIBEREHD2016-ENG

• Poster presentation (AEEH 2016): results of efficacy and safety of combinations of direct-acting antivirals in patients with genotype 3 hepatitis c: Hepa-C cohort.
• Poster presentation (and short oral paper in the “club joven AEEH” seminar 2016): efficacy and safety of combinations of direct-acting antivirals in elderly patients: Hepa-C registry.
• Oral paper (prize for “best clinical abstract” EASL 2016): treatment of hepatitis c virus in patients with advanced cirrhosis: always justified? analysis of the Hepa-C registry.
• Poster presentation (EASL 2016): effectiveness and safety of sofosbuvir/ledipasvir treatment for monoinfected genotype 1 hcv patients in real-life clinical practice: results from Spanish Hepa-C cohort.
• Poster presentation (EASL 2016): effectiveness and safety of ombitasvir, paritaprevir, ritonavir and dasabuvir patients with genotype 1 chronic hepatitis c virus infection: results from the Spanish real-world cohort.
• Poster presentation (EASL 2016): can we continue after liver transplantation with hcv treatment started on list? (Hepa-C registry case series).
• Poster presentation (EASL 2016): efficacy and tolerability of interferon-free antiviral therapy in kidney transplant (kt) recipients with chronic hepatitis c: real-life data from the Spanish national registry (Hepa-C).
• Poster presentation (EASL 2016): safety and efficacy of sofosbuvir plus simeprevir in a Spanish cohort of 622 cirrhotic patients infected with genotypes 1 or 4.
Articles in scientific journals
• Carrillo CF, Crespo G, de la Revilla J, Castells L, Buti M, Montero JL, Fábrega E, Fernández I, Serrano- Millán C, Hernández V, Calleja JL, Londoño MC. Successful continuation of HCV treatment following liver transplantation. Transplantation. 2016 Dec 1.
• Alonso S, Riveiro-Barciela M, Fernandez I, Rincón D, Real Y, Llerena S, Gea F, Olveira A, Fernandez- Carrillo C, Polo B, Carrión JA, Gómez A, Devesa MJ, Baliellas C, Castro Á, Ampuero J, Granados R, Pascasio JM, Rubín A, Salmeron J, Badia E, Planas JM, Lens S, Turnes J, Montero JL, Buti M, Esteban R, Fernández-Rodríguez CM. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. J Viral Hepat. 2016 Dec 9.
• Three manuscripts were sent off in 2016 and accepted for early 2017, which will be included among the achievements for 2017.
Others
• We have continued increasing the sample and promoting participation. There are at present over 6700 patients from 76 different national centres.
• The new Elbasvir/Grazoprevir and Sofosbuvir/Velpatasvir regimens have been included. A package of software improvements has been applied which will make a significant improvement to reducing biases and to improving user experience.
13243